The New 7.2mg Wegovy Pen: How It Works and When It's Arriving in the UK

What is the 7.2mg Wegovy pen?#

The 7.2mg dose is the highest strength of Wegovy (semaglutide) now licensed in the UK for weight management. It's designed for people who've plateaued on the standard 2.4mg maintenance dose and need a bit more support to keep losing weight.

The dedicated 7.2mg pen is now available. Rather than a single multi-dose device like the lower-strength FlexTouch pens, the 7.2mg format comes as a box of four single-use pens — one for each weekly injection in the month.

How is 7.2mg administered?#

Each box of Wegovy 7.2mg contains four individual single-use pens. You use one pen per week: take the cap off, inject, and dispose of the entire pen afterwards. There are no needles to attach and remove, no dose dial to count down, and no single pen to keep track of across the month — just one pen per week, then it's done.

This is a cleaner, more straightforward format than the existing FlexTouch pens used for lower doses (0.25mg through to 2.4mg), which are multi-dose devices pre-filled with a month's worth of medication that require a fresh needle to be attached before each weekly injection.

The switch to single-use pens for the 7.2mg dose comes down to volume. The higher dose requires more liquid than can be practically held across four doses in a single multi-dose pen, so individual single-use pens were the most accurate and safe way to deliver it.

What changed from the previous approach?#

Before the dedicated pen became available, the only way to reach a 7.2mg weekly dose was to inject three separate 2.4mg doses in a single week using the existing FlexTouch pens. This was a legitimate, medically supervised approach — not an off-label workaround — but it was a temporary solution while the dedicated device was being developed and manufactured.

With the 7.2mg single-use pens now on the market, that three-injection approach is no longer necessary. Patients stepping up to 7.2mg can now do so with a single weekly injection, just as they would at any lower dose.

How much weight does 7.2mg Wegovy lead to?#

The evidence for the 7.2mg dose comes primarily from the STEP UP trial, a 72-week Phase 3b study that looked specifically at this higher dose of semaglutide. In that trial, participants on 7.2mg achieved an average body weight reduction of approximately 18.7% to 20.7% — meaningfully more than the 15.6% to 17.5% seen with the standard 2.4mg dose in the same study.

That's a notable difference, and it makes a real case for stepping up in patients who have plateaued at 2.4mg and still have clinical reasons to lose further weight. It's worth being clear, though, that these are averages: individual results vary, and some people will respond more or less than the trial mean.

Side effects at the higher dose#

It's worth being upfront about this: gastrointestinal side effects tend to become slightly more noticeable as the dose increases. Nausea, reflux, constipation, and diarrhoea are the most commonly reported issues with semaglutide generally, and the STEP UP trial (which looked specifically at the 7.2mg dose) found a similar pattern, with GI symptoms occurring somewhat more frequently than at 2.4mg, though most were mild to moderate and settled with time.

This is exactly why prescribers don't jump straight to 7.2mg. Dose escalation happens gradually, in the same way it does when starting Wegovy at all, so your body has time to adjust. If you're finding the current dose genuinely difficult to tolerate, going higher usually isn't the right move, and your prescriber should talk this through with you properly before recommending a step up.

Cost and access: NHS versus private prescriptions#

Access to Wegovy in the UK broadly splits into two routes: NHS specialist weight management services, and private prescriptions through registered pharmacies.

On the NHS, semaglutide is available under NICE guidance (TA875) for adults with a BMI of 35 or above with a weight-related health condition, or BMI 30 to 34.9 with a referral to a specialist weight management service. Availability varies quite a lot by region and NHS trust, and waiting lists for these services can be long. If prescribed via NHS primary care, you'd typically pay the standard prescription charge per item, currently £9.90 in England (Wales, Scotland, and Northern Ireland don't charge for NHS prescriptions).

Privately, the eligibility bar is often a bit different, usually based on the medicine's licensed indication (BMI of 30+, or 27+ with a weight-related condition) plus a clinical assessment by a prescriber. This is where a lot of people end up going, particularly if NHS routes aren't accessible where they live, or the wait is too long.

At Totiva, current Wegovy pricing per month's supply looks like this:

• 0.25mg, 0.5mg, or 1mg: £92.88
• 1.7mg: £143.88
• 2.4mg: £188.88
• 7.2mg: £199.88

What's worth noting is that stepping up from 2.4mg to 7.2mg isn't a huge price jump, roughly £11 more per month, despite being a much higher dose. There's also a tablet version of Wegovy (oral semaglutide) available if needles aren't your thing, ranging from £99 to £165 depending on strength.

You can view current pricing and check eligibility through a free online consultation at Totiva's weight loss service page. The consultation itself is free, you only pay if a clinician approves treatment for you, and there's no subscription tie-in.

How does this compare to Mounjaro at higher doses?#

It's a fair question, since Mounjaro (tirzepatide) is the other major weight loss injection available in the UK, and it goes up to 15mg. The two drugs have been studied in separate trial programmes — the STEP trials for semaglutide and the SURMOUNT trials for tirzepatide — and at their respective higher doses, tirzepatide tends to produce somewhat greater average weight loss. That said, the two haven't been tested directly against each other in the same trial, so comparisons should be taken with a pinch of salt.

In practice, which one suits you better depends on how your body responds, side effect tolerance, and personal preference. Both are available through Totiva, and a pharmacist can talk through the pros and cons of each during your consultation.

Recycling and disposal#

Because the 7.2mg format uses four single-use pens per month rather than one multi-dose pen, it does mean more plastic per month. Novo Nordisk runs a scheme called PenCycle, which lets UK patients request a free postage-paid box to return used pens for recycling, rather than binning them or putting them through general sharps disposal alone. It's a straightforward way to reduce the environmental footprint of the single-use pen format.

Is the 7.2mg dose right for you?#

Not everyone needs to go this high, and that's genuinely fine. A lot of people do perfectly well maintaining their results at 1.7mg or 2.4mg long term. The 7.2mg dose is really there as an extra option for people who've hit a plateau and still have clinical reasons to keep losing weight.

Higher doses are usually only considered when:

• You've been on 2.4mg for at least 4 weeks
• Your weight loss has stalled before reaching your target
• You're tolerating your current dose well, without significant side effects
• There's still a clear clinical reason to continue losing weight

If all of these apply, it's worth raising 7.2mg with your prescriber. If you're already managing well at a lower dose, there's rarely a reason to push higher just because a stronger option exists.

If you're weighing up whether a higher dose, a different medication, or starting treatment for the first time makes sense for you, a pharmacist-led consultation is a good place to start. Totiva's online weight loss consultations are free, run by UK-registered clinicians, and there's no pressure to commit to anything before you've had proper advice.